)
Unicycive Therapeutics (UNCY) investor relations material
Unicycive Therapeutics Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Voting matters and shareholder proposals
Three directors were elected to serve until the 2027 Annual Meeting or until successors are appointed, with detailed vote counts provided for each nominee.
The appointment of Grassi & Co. CPAs, P.C. as independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified by shareholders, with the majority voting in favor.
Board of directors and corporate governance
Directors elected include Dr. Shalabh Gupta, Dr. Sandeep Laumas, and D. Sarawati Kenkare-Mitra, each receiving a majority of votes cast.
Audit committee and external auditor matters
Grassi & Co. CPAs, P.C. was approved as the external auditor for the upcoming fiscal year, with minimal opposition and abstentions.
- OLC targets hyperphosphatemia's unmet needs with low pill burden and strong launch readiness.UNCY
Corporate presentation22 Jun 2026 - PDUFA decision for a novel phosphate binder may transform dialysis care with a streamlined launch.UNCY
25th Annual Needham Virtual Healthcare Conference6 Jun 2026 - Regulatory delay for OLC is manufacturing-related, with rapid launch and funding readiness upon approval.UNCY
H.C. Wainwright 4th Annual Kidney Virtual Conference6 Jun 2026 - Biotech seeks up to $150M for kidney disease therapies, leveraging at-the-market sales.UNCY
Registration filing5 Jun 2026 - OLC showed favorable safety, efficacy, and reduced pill burden for dialysis patients.UNCY
Investor presentation1 Jun 2026 - OLC targets hyperphosphatemia with FDA review set for June 2026 and strong launch readiness.UNCY
Company presentation1 Jun 2026 - Net loss improved to $11.1M, pivotal trial success supports NDA, and cash reserves remain strong.UNCY
Q2 20241 Jun 2026 - FDA accepted NDA for OLC; net loss narrowed, $50M raised, and cash supports operations into 2026.UNCY
Q3 20241 Jun 2026 - OLC NDA under FDA review; net loss widens to $37.8M, cash supports operations into 2026.UNCY
Q4 20241 Jun 2026
Next Unicycive Therapeutics earnings date
Next Unicycive Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)